痙縮治療の世界市場

痙縮治療の世界市場は2030年までに72億米ドルに達する

2024年に59億米ドルと推定される痙縮治療の世界市場は、分析期間2024-2030年にCAGR 3.2%で成長し、2030年には72億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである痙縮薬物療法は、CAGR 4.0%を記録し、分析期間終了時には46億米ドルに達すると予測されます。痙縮理学療法分野の成長率は、分析期間中CAGR 1.9%と推定されます。

米国市場は16億米ドルと推定、中国はCAGR6.2％で成長予測

米国の痙縮治療市場は2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.5%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界の痙縮治療市場- 主要動向と促進要因まとめ

筋緊張障害の管理：新たな治療法が痙縮ケアと患者の転帰をどのように再定義しているか

痙縮とは何か、なぜ神経学的治療領域としてますます優先されるようになったのか？

痙縮は、不随意的な筋肉の硬直、誇張された反射、受動的な動きに対する抵抗を特徴とする神経筋疾患であり、中枢神経系の損傷に起因することが多いです。一般的な基礎原因には、多発性硬化症（MS）、脳性麻痺（CP）、外傷性脳損傷（TBI）、脳卒中、脊髄損傷などがあります。痙縮は、可動性や巧緻性を損なうだけでなく、関節拘縮、疼痛、長期的な障害の原因となり、患者のQOLや介護者の負担に大きな影響を与えます。

診断能力や急性期後のケアシステムが世界的に改善されるにつれ、痙縮に関連する合併症に対する認識や発見が高まっています。この疾患は、単なる症状としてではなく、QOLに広く影響する修正可能な治療対象として見なされるようになってきています。現在、臨床管理には、薬理学的、リハビリテーション的、外科的、神経調節的アプローチにまたがる集学的介入が含まれています。患者中心の機能回復ソリューションに対する需要の高まりにより、痙縮治療の適用範囲は小児から成人まで広がっています。

主要な治療アプローチと患者管理を変えるイノベーションとは？

薬物療法は依然として治療の第一選択であり、バクロフェン、チザニジン、ジアゼパム、ダントロレンなどの経口鎮痙薬が一般的に処方されています。しかし、これらの薬剤は鎮静、低血圧、肝毒性などの全身性の副作用を生じることが多く、長期間の使用には限界があります。その結果、A型ボツリヌス毒素（BoNT-A）注射のような局所療法が支持されるようになりました。これらの神経筋遮断剤は、神経筋接合部でのアセチルコリン放出を選択的に阻害するため、全身への影響が少なく、標的を絞った緩和が可能です。Botox（Allergan）、Dysport（Ipsen）、Xeomin（Merz）などのブランドがこのセグメントを独占しており、上肢痙縮と下肢痙縮にわたる広範な臨床試験データに支えられています。

髄腔内バクロフェン療法（ITB）は、重度の全般性痙縮に対するもう一つの先進的治療法です。これは、プログラム可能なポンプを埋め込み、バクロフェンを脊髄に直接投与するもので、全身への曝露を減らし、有効性を向上させる。ITBは、脳性麻痺、脊髄損傷、重度の脳卒中後痙縮の患者に特に有効です。腱離断術や選択的背側指節骨切り術などの外科的手術は、難治性の症例や変形矯正が必要な場合に行われます。理学療法と作業療法は、筋ストレッチ、スプリント、機能再教育に重点を置き、依然として不可欠な補助療法です。

新たな技術革新としては、経頭蓋磁気刺激（TMS）や電気刺激療法などの神経調節技術があり、これらは脊髄反射回路を調節し、随意運動制御を改善することを目的としています。デジタル治療法、AIを利用した歩行分析、装着型筋電図（EMG）センサーも痙縮管理経路に組み込まれつつあり、客観的なモニタリングとオーダーメイドの治療調整を提供しています。幹細胞研究や再生療法は、特に脊髄損傷や脳損傷の症例において、神経可塑性強化のための初期の探索段階にあります。

痙縮ケアの成長を牽引する地域と提供モデルの進化は？

北米が世界の痙縮治療市場をリードしているのは、疾患に対する意識の高さ、先進治療薬へのアクセスの広さ、神経科やリハビリテーションセンターの強力なエコシステムによるものです。米国はBoNT-A治療の主要市場であり、保険適用範囲が広く、患者支援団体が早期診断と介入を支援しています。メディケイドや退役軍人会などの政府出資プログラムも、外科的治療やデバイスベースの治療をカバーしており、十分なサービスを受けていない人々へのアクセスを拡大しています。

欧州もこれに続き、ドイツ、フランス、英国、北欧諸国などでボツリヌス毒素療法が広く採用されています。国の医療サービスでは薬物療法や外科的治療に対する償還が行われ、研究機関では薬物療法とロボット治療の併用といった新しい技術の評価が活発に行われています。この地域のリハビリテーションネットワークや脳卒中病棟は、痙縮の統合管理を重視しており、多くの場合、リハビリテーション医、神経科医、整形外科医、セラピストを含む集学的チームを用いています。

アジア太平洋は、中国、日本、インド、韓国などの国々における脳卒中や外傷の発生率の増加、リハビリテーションへのアクセスの改善、医療投資の増加により、新たなホットスポットとなっています。BoNT-A療法やITB療法に対する認知度や専門医の有無にはばらつきがあるもの、都市部では需要が急増しています。ラテンアメリカと中東は、医療ツーリズム、遠隔医療相談、障害者ケアに焦点を当てた官民パートナーシップに支えられ、痙縮サービスを徐々に拡大しています。

何が市場成長を促進し、どこで将来の治療フロンティアが出現すると予想されるか？

世界の痙縮治療市場の成長は、神経血管障害や神経変性障害の有病率の上昇、受傷後の生存率の向上、低侵襲で個別化された治療オプションの出現など、いくつかの要因によってもたらされます。ヘルスケアシステムが長期的な機能的転帰と障害軽減を優先するにつれ、痙縮管理はより広範な神経リハビリテーションの枠組みに組み込まれつつあります。注射可能な生物製剤やプログラム可能なドラッグデリバリーシステムの採用が増加していることは、ターゲットを絞った持続可能な治療パラダイムへのシフトを反映しています。

パイプラインには、効果持続時間が長く、安全性プロファイルが改善され、発現が早い次世代ボツリヌス毒素製剤が含まれます。各社はバイオシミラーの開発を進めており、小児や外傷後の患者を対象とした適応症の拡大を図っています。BoNT-Aとロボット工学や機能的電気刺激などの併用療法は、運動機能を改善し、介護者の依存を軽減することで有望視されています。さらに、利用者のデータに基づいて治療強度を適応させるAI対応のリハビリテーション・プラットフォームが、医療提供者や支払者の間で関心を集めています。

治療の成功の定義が筋緊張の緩和だけでなく、QOL指標、機能的自立、患者が報告するアウトカムなどへと進化するにつれて、痙縮治療市場は総合的な技術対応領域へと拡大することになります。統合ケアモデル、神経技術、デジタルバイオマーカートラッキングへの戦略的投資は、世界の痙縮ケアの未来を形作る上で極めて重要な役割を果たすと思われます。

セグメント

タイプ（痙縮薬物療法、痙縮理学療法、痙縮外科治療）、投与経路（経口投与、非経口投与）、適応症（脳性麻痺適応症、多発性硬化症適応症、外傷性脳損傷適応症、その他適応症）、エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、在宅介護施設エンドユーザー、専門クリニックエンドユーザー、診断センターエンドユーザー）

調査対象企業の例

• AbbVie Inc.（Allergan）
• Acorda Therapeutics, Inc.
• Amneal Pharmaceuticals, Inc.
• Assertio Therapeutics, Inc.
• Beximco Pharmaceuticals Ltd.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc（GSK）
• InMed Pharmaceuticals Inc.
• Ipsen Biopharmaceuticals, Inc.
• Jazz Pharmaceuticals plc
• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer Inc.
• Piramal Enterprises Ltd.
• Revance Therapeutics, Inc.
• RVL Pharmaceuticals Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB Pharma S.A.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Spasticity Treatment Market to Reach US$7.2 Billion by 2030

The global market for Spasticity Treatment estimated at US$5.9 Billion in the year 2024, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Spasticity Drug Therapy, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Spasticity Physical Therapy segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 6.2% CAGR

The Spasticity Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Spasticity Treatment Market - Key Trends & Drivers Summarized

Managing Muscle Tone Disorders: How Emerging Therapies Are Redefining Spasticity Care and Patient Outcomes

What Is Spasticity and Why Is It Becoming an Increasingly Prioritized Neurological Treatment Area?

Spasticity is a neuromuscular condition characterized by involuntary muscle stiffness, exaggerated reflexes, and resistance to passive movement, often resulting from central nervous system damage. Common underlying causes include multiple sclerosis (MS), cerebral palsy (CP), traumatic brain injury (TBI), stroke, and spinal cord injury. Spasticity not only impairs mobility and dexterity but also contributes to joint contractures, pain, and long-term disability, significantly affecting patient quality of life and caregiver burden.

As diagnostic capabilities and post-acute care systems improve globally, there is greater awareness and detection of spasticity-related complications. The condition is increasingly seen not just as a symptom but as a modifiable therapeutic target with broad quality-of-life implications. Clinical management now includes multidisciplinary interventions spanning pharmacologic, rehabilitative, surgical, and neuromodulatory approaches. The growing demand for patient-centric, function-restoring solutions is expanding the scope of spasticity treatment across both pediatric and adult populations.

What Are the Leading Therapeutic Approaches and Which Innovations Are Transforming Patient Management?

Pharmacological therapy remains the first line of treatment, with oral antispasmodics such as baclofen, tizanidine, diazepam, and dantrolene being commonly prescribed. However, these agents often produce systemic side effects like sedation, hypotension, or hepatotoxicity, limiting long-term use. As a result, focal therapies such as botulinum toxin type A (BoNT-A) injections have gained traction. These neuromuscular blocking agents selectively inhibit acetylcholine release at the neuromuscular junction, offering targeted relief with fewer systemic effects. Brands like Botox (Allergan), Dysport (Ipsen), and Xeomin (Merz) dominate this segment, supported by extensive clinical trial data across upper and lower limb spasticity.

Intrathecal baclofen therapy (ITB) is another advanced intervention for severe generalized spasticity. This involves implanting a programmable pump to deliver baclofen directly to the spinal cord, reducing systemic exposure and improving efficacy. ITB is particularly beneficial for patients with cerebral palsy, spinal cord injury, or severe post-stroke spasticity. Surgical options, including tendon release and selective dorsal rhizotomy, are reserved for refractory cases or when deformity correction is needed. Physical and occupational therapy remain essential adjuncts, focusing on muscle stretching, splinting, and functional retraining.

Emerging innovations include neuromodulation techniques such as transcranial magnetic stimulation (TMS) and electrical stimulation therapies, which aim to modulate spinal reflex circuits and improve voluntary motor control. Digital therapeutics, AI-enabled gait analysis, and wearable electromyography (EMG) sensors are also being integrated into spasticity management pathways, providing objective monitoring and tailored therapy adjustments. Stem cell research and regenerative therapies are in early exploratory phases for neuroplasticity enhancement, especially in spinal cord and cerebral injury cases.

Which Regions Are Driving Growth in Spasticity Care and How Are Delivery Models Evolving?

North America leads the global spasticity treatment market due to high disease awareness, widespread access to advanced therapeutics, and a strong ecosystem of neurology and rehabilitation centers. The U.S. is a key market for BoNT-A treatments, with extensive insurance coverage and patient advocacy groups supporting early diagnosis and intervention. Government-funded programs such as Medicaid and Veterans Affairs also cover surgical and device-based treatments, expanding access to underserved populations.

Europe follows closely, with strong adoption of botulinum toxin therapy across countries like Germany, France, the UK, and the Nordics. National health services provide reimbursement for pharmacologic and surgical treatments, while research institutions are active in evaluating newer techniques such as combined pharmacologic and robotic therapy. Rehabilitation networks and stroke units in the region emphasize integrated spasticity management, often using multidisciplinary teams that include physiatrists, neurologists, orthopedic surgeons, and therapists.

Asia-Pacific is an emerging hotspot, driven by increasing stroke and trauma incidence, improved rehabilitation access, and rising healthcare investments in countries such as China, Japan, India, and South Korea. Although awareness and specialist availability remain uneven, urban centers are witnessing rapid growth in demand for BoNT-A and ITB therapies. Latin America and the Middle East are gradually expanding spasticity services, supported by medical tourism, telehealth consultations, and public-private partnerships focused on disability care.

What Is Fueling Market Growth and Where Are Future Treatment Frontiers Expected to Emerge?

The growth in the global spasticity treatment market is driven by several factors including rising prevalence of neurovascular and neurodegenerative disorders, improved post-injury survival rates, and the emergence of minimally invasive, personalized therapy options. As healthcare systems prioritize long-term functional outcomes and disability reduction, spasticity management is being integrated into broader neurorehabilitation frameworks. The increasing adoption of injectable biologics and programmable drug delivery systems reflects a shift toward targeted, sustainable treatment paradigms.

Pipeline opportunities include next-generation botulinum toxin formulations with longer duration of effect, improved safety profiles, and faster onset. Companies are developing biosimilars and expanded indication sets for pediatric and post-trauma populations. Combination therapies-such as BoNT-A with robotics or functional electrical stimulation-are showing promise in improving motor function and reducing caregiver dependence. Additionally, AI-enabled rehabilitation platforms that adapt therapy intensity based on user data are gaining interest among providers and payers.

As the definition of therapeutic success evolves beyond muscle tone reduction to include quality-of-life metrics, functional independence, and patient-reported outcomes, the spasticity treatment market is set to expand into a holistic, tech-enabled domain. Strategic investments in integrated care models, neurotechnology, and digital biomarker tracking will play a pivotal role in shaping the future of spasticity care worldwide.

SCOPE OF STUDY:

The report analyzes the Spasticity Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Spasticity Drug Therapy, Spasticity Physical Therapy, Surgical Treatment for Spasticity); Administration Route (Oral Administration, Parenteral Administration); Indication (Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication, Other Indications); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use, Diagnostic Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc. (Allergan)
• Acorda Therapeutics, Inc.
• Amneal Pharmaceuticals, Inc.
• Assertio Therapeutics, Inc.
• Beximco Pharmaceuticals Ltd.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc (GSK)
• InMed Pharmaceuticals Inc.
• Ipsen Biopharmaceuticals, Inc.
• Jazz Pharmaceuticals plc
• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer Inc.
• Piramal Enterprises Ltd.
• Revance Therapeutics, Inc.
• RVL Pharmaceuticals Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB Pharma S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Spasticity Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Neurological Disorders Drives Demand for Spasticity Management Therapies
  • Increased Awareness of Stroke Rehabilitation Enhances Early Diagnosis and Intervention Rates
  • Growing Use of Botulinum Toxin Injections Supports Non-Surgical Treatment Pathways
  • Development of Targeted Drug Delivery Mechanisms Improves Efficacy of Pharmacological Interventions
  • Surge in Clinical Trials Evaluating Novel Antispastic Agents Expands Therapeutic Pipeline
  • Integration of Physical Therapy With Pharmacologic Protocols Promotes Multimodal Care Models
  • Increased Availability of Intrathecal Baclofen Pumps Boosts Patient-Specific Treatment Adoption
  • Progress in Neurorehabilitation Robotics and Exoskeletons Supports Functional Recovery
  • Rising Demand for Home-Based Rehabilitation Technologies Enhances Patient Engagement
  • Expansion of Pediatric Spasticity Treatment Programs Broadens Access to Early Interventions
  • Use of Digital Health and Mobile Apps Supports Monitoring of Spasticity Severity and Outcomes
  • Government Support for Disability Management Enhances Reimbursement and Insurance Access
  • Collaboration Between Neurologists, Orthopedists, and Rehab Specialists Optimizes Treatment Outcomes
  • Adoption of Customized Orthotic Devices Improves Mobility in Spasticity Patients
  • Increased Focus on Post-Surgical Spasticity Management Drives Innovation in Adjunct Therapies
  • Emergence of Gene Therapy Research for Spasticity Signals Long-Term Potential
  • Rising Prevalence of Cerebral Palsy and Multiple Sclerosis Fuels Chronic Care Requirements
  • Advancement in MRI and EMG-Guided Interventions Supports Precision Targeting
  • Educational Campaigns and Advocacy Support Early Referral and Diagnosis
  • Growing Interest in Cannabinoid-Based Spasticity Medications Drives Regulatory Submissions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Spasticity Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Spasticity Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Spasticity Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Spasticity Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Spasticity Physical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Surgical Treatment for Spasticity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Surgical Treatment for Spasticity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Home Care Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Home Care Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Cerebral Palsy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Cerebral Palsy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Traumatic Brain Injury Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Traumatic Brain Injury Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 30: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 31: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 34: USA Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: USA 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 36: USA Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: USA 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• CANADA
  • TABLE 40: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Canada 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 42: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Canada 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 46: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Canada 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• JAPAN
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 48: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Japan 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 52: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Japan 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 54: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Japan 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• CHINA
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 58: China Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: China 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 60: China Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: China 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• EUROPE
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 64: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 65: Europe 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 66: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Europe 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 70: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Europe 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 72: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Europe 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• FRANCE
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 76: France Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: France 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 78: France Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: France 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• GERMANY
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 82: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Germany 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 84: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Germany 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 88: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Germany 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• ITALY
  • TABLE 90: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Italy 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 94: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Italy 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 96: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Italy 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• UNITED KINGDOM
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 98: UK Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: UK 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 100: UK Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: UK 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 102: UK Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 103: UK 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• SPAIN
  • TABLE 106: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 107: Spain 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 108: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Spain 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 112: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 113: Spain 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• RUSSIA
  • TABLE 114: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 115: Russia 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 116: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Russia 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 118: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 119: Russia 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 120: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 121: Russia 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Rest of Europe 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 125: Rest of Europe 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 126: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 127: Rest of Europe 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• ASIA-PACIFIC
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 131: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
  • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 133: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 136: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 137: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 138: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 139: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• AUSTRALIA
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 140: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Australia 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 142: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 143: Australia 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 144: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 145: Australia 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 146: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Australia 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• INDIA
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 148: India Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 149: India 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 150: India Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 151: India 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 152: India Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: India 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 154: India Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 155: India 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• SOUTH KOREA
  • TABLE 156: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 157: South Korea 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 158: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: South Korea 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 160: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 161: South Korea 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 162: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 163: South Korea 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 164: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 167: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 168: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 169: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 170: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• LATIN AMERICA
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 172: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 173: Latin America 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
  • TABLE 174: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 175: Latin America 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 176: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Latin America 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 178: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 179: Latin America 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 180: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 181: Latin America 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• ARGENTINA
  • TABLE 182: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Argentina 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 184: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 185: Argentina 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 186: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 187: Argentina 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 188: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Argentina 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• BRAZIL
  • TABLE 190: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 191: Brazil 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 192: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 193: Brazil 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 194: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Brazil 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 196: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 197: Brazil 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• MEXICO
  • TABLE 198: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 199: Mexico 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 200: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Mexico 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 202: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 203: Mexico 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 204: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 205: Mexico 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 206: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Latin America 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 209: Rest of Latin America 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 210: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 211: Rest of Latin America 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 212: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Latin America 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• MIDDLE EAST
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 214: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 215: Middle East 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
  • TABLE 216: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 217: Middle East 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 218: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Middle East 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 220: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 221: Middle East 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 222: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 223: Middle East 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• IRAN
  • TABLE 224: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Iran 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 226: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 227: Iran 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 228: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 229: Iran 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 230: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Iran 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• ISRAEL
  • TABLE 232: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 233: Israel 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 234: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 235: Israel 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 236: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Israel 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 238: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 239: Israel 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• SAUDI ARABIA
  • TABLE 240: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 241: Saudi Arabia 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Saudi Arabia 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 244: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 245: Saudi Arabia 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 246: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 247: Saudi Arabia 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 248: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: UAE 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 250: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 251: UAE 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 252: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 253: UAE 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 254: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: UAE 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 256: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 257: Rest of Middle East 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 259: Rest of Middle East 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 260: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Middle East 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 262: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 263: Rest of Middle East 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
• AFRICA
  • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 264: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 265: Africa 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
  • TABLE 266: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Africa 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
  • TABLE 268: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 269: Africa 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
  • TABLE 270: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 271: Africa 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030

IV. COMPETITION